The Zhitong Finance App learned that Lyon released a research report saying that the stock price of Cansino Biotech (06185) surged more than 50% in half a day, mainly driven by the positive results of Moderna (MRNA.US)'s phase III clinical trial of the mRNA cancer vaccine. Moderna's Interpath-001 phase III study (involving 1,137 high-risk melanoma patients), whose personalized mRNA cancer vaccine IntiSmeran autogene combined with pembrolizumab reached the primary and secondary endpoints of relapse-free survival (RFS) and survival without distant metastasis (DMFS), and showed no new safety signals. Moderna's stock price rose 177%. This is the first mRNA cancer vaccine or individualized novel antigen therapy to achieve positive results in phase III clinical trials.

Lyon pointed out that since Moderna is conducting clinical studies on the same platform for lung cancer, kidney cancer, and bladder cancer, this success is a platform-level valuation reassessment. Cansino Biologics is positioned on the same technical path. Currently, its rhabdomyosarcoma program is in the investigator-initiated clinical trial (IIT) stage, and the glioma project is still awaiting pre-clinical approval. The Group's development route and antigen design are roughly similar to Moderna. The main difference is its three-component lipid nanoparticle (LNP) system, which is safer than traditional formulations and may support a stronger cellular immune response.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.